Entity Common Stock, Shares Outstanding of GT Biopharma, Inc. from 15 Aug 2011 to 06 Nov 2025

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
GT Biopharma, Inc. quarterly Entity Common Stock, Shares Outstanding in shares history and change rate from 15 Aug 2011 to 06 Nov 2025.
  • GT Biopharma, Inc. Entity Common Stock, Shares Outstanding for the quarter ending 06 Nov 2025 was 10,636,135, a 376% increase year-over-year.
Source SEC data
View on sec.gov
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

GT Biopharma, Inc. Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 10,636,135 +8,401,807 +376% 06 Nov 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 3,557,502 +1,323,174 +59% 08 Aug 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 2,234,328 +853,695 +62% 19 Feb 2025 10-K/A 14 Apr 2025 2024 FY
Q3 2024 2,234,328 -39,184,671 -95% 10 Nov 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 2,234,328 -38,405,360 -95% 10 Aug 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 1,380,633 -35,428,638 -96% 26 Mar 2024 10-K 26 Mar 2024 2023 FY
Q3 2023 41,418,999 +8,861,279 +27% 01 Nov 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 40,639,688 +10,138,971 +33% 07 Aug 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 36,809,271 +4,686,427 +15% 30 Mar 2023 10-K 30 Mar 2023 2022 FY
Q3 2022 32,557,720 +1,975,366 +6.5% 31 Oct 2022 10-Q 31 Oct 2022 2022 Q3
Q2 2022 30,500,717 16 May 2022 10-Q 16 May 2022 2022 Q1
Q1 2022 32,122,844 +3,728,884 +13% 28 Mar 2022 10-K 28 Mar 2022 2021 FY
Q3 2021 30,582,354 -47,686,260 -61% 12 Nov 2021 10-Q 10 Nov 2021 2021 Q3
Q1 2021 28,393,960 -42,208,473 -60% 12 Apr 2021 10-K 16 Apr 2021 2020 FY
Q3 2020 78,268,614 +10,836,416 +16% 11 Nov 2020 10-Q 13 Nov 2020 2020 Q3
Q2 2020 76,560,862 +10,415,980 +16% 11 Aug 2020 10-Q/A 18 Aug 2020 2020 Q2
Q1 2020 70,602,433 +19,228,015 +37% 23 Mar 2020 10-K 27 Mar 2020 2019 FY
Q3 2019 67,432,198 +17,204,220 +34% 14 Nov 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 66,144,882 +16,026,905 +32% 11 Aug 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 51,374,418 +1,256,440 +2.5% 06 Mar 2019 10-K 29 Mar 2019 2018 FY
Q3 2018 50,227,978 +460,000 +0.92% 14 Nov 2018 10-Q 14 Nov 2018 2018 Q3
Q2 2018 50,117,977 +49,621,536 +9995% 14 Aug 2018 10-Q 14 Aug 2018 2018 Q2
Q1 2018 50,117,978 -72,794,890 -59% 28 Feb 2018 10-K 01 Mar 2018 2017 FY
Q3 2017 49,767,978 +19,526,673 +65% 14 Nov 2017 10-Q 14 Nov 2017 2017 Q3
Q2 2017 496,441 -26,419,518 -98% 11 Aug 2017 10-Q 11 Aug 2017 2017 Q2
Q1 2017 122,912,868 +101,395,647 +471% 28 Mar 2017 10-K/A 28 Feb 2018 2016 FY
Q3 2016 30,241,305 -569,758,695 -95% 14 Nov 2016 10-Q/A 28 Feb 2018 2016 Q3
Q2 2016 26,915,959 -573,084,041 -96% 01 Aug 2016 10-Q/A 28 Feb 2018 2016 Q2
Q1 2016 21,517,221 -578,397,263 -96% 27 Mar 2016 10-K/A 28 Feb 2018 2015 FY
Q3 2015 600,000,000 +8,285,516 +1.4% 13 Nov 2015 10-Q 13 Nov 2015 2015 Q3
Q2 2015 600,000,000 14 Aug 2015 10-Q 14 Aug 2015 2015 Q2
Q1 2015 599,914,484 27 Mar 2015 10-K 31 Mar 2015 2014 FY
Q4 2014 591,714,484 07 Jan 2015 10-Q 08 Jan 2015 2014 Q3
Q3 2014 591,714,484 23 Oct 2014 10-K 18 Nov 2014 2012 FY
Q3 2012 457,207,313 +241,784,697 +112% 30 Sep 2012 10-Q 21 Nov 2012 2012 Q3
Q2 2012 364,299,838 30 Jun 2012 10-Q/A 13 Sep 2012 2012 Q2
Q1 2012 269,299,838 13 Apr 2012 10-K 16 Apr 2012 2011 FY
Q4 2011 238,622,616 21 Nov 2011 10-Q 21 Nov 2011 2011 Q3
Q3 2011 215,422,616 15 Aug 2011 10-Q/A 12 Sep 2011 2011 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.